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An Expectation-Maximization Algorithm for the Analysis of Allelic
Expression Imbalance
M. D. Teare, J. Heighway, and M. F. Santiba´n˜ez Koref
A signiﬁcant proportion of the variation between individuals in gene expression levels is genetic, and it is likely that
these differences correlate with phenotypic differences or with risk of disease. Cis-acting polymorphisms are important
in determining interindividual differences in gene expression that lead to allelic expression imbalance, which is the
unequal expression of homologous alleles in individuals heterozygous for such a polymorphism. This expression im-
balance can be detected using a transcribed polymorphism, and, once it is established, the next step is to identify the
polymorphisms that are responsible for or predictive of allelic expression levels. We present an expectation-maximization
algorithm for such analyses, providing a formal statistical framework to test whether a candidate polymorphism is
associated with allelic expression differences.
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Over the past few years, there has been increasing interest
in the genetic basis of interindividual differences in gene
expression. Particular attention has been paid to the iden-
tiﬁcation of genetic variation affecting expression in cis.1–
3 In individuals heterozygous for a polymorphism affect-
ing expression in cis, the amounts of mRNA originating
from each allele are not equal. Such allelic expression im-
balance (AEI) can bemeasured in individualsheterozygous
for a transcribed polymorphism. The relative transcript
levels of one allele with respect to the other are often easier
to measure than absolute levels, since each allele acts as
a parallel internal control for the other. The use of AEI for
detecting cis-acting genetic variation is also attractive be-
cause many sources of expression variability, such as en-
vironmental inﬂuences, are likely to act in trans and to
affect both alleles.
Once a gene showing differences in allelic expression
has been identiﬁed, interest may turn to the causes and
the potential consequences of these differences. Discov-
ering the latter may require the identiﬁcation of the caus-
ative polymorphism(s) or, at least, the polymorphisms
that are predictive for allelic expression levels. This infor-
mation can help to identify factors that modify disease
risk or that modulate interindividual differences in the
response to drugs or to other environmental challenges.
Although it is to be expected that causative polymor-
phisms will often be located in the promoter region, we
should bear in mind that elements affecting transcription
in cis can be widely distributed throughout a locus and
can even be located in neighboring loci, an extreme ex-
ample of this being the action of Xist.4 Thus, locating cis-
acting variation with the use of functional assays can be
a laborious task that may be simpliﬁed if information
about the location of the sequences of interest is available.
A second reason for the interest in allelic expression
differences is that they can provide evidence in vivo of
the relevance of polymorphisms that have been shown
to be able to affect transcription in vitro. The assays used
rely often on cell lines and reporter constructs, which are
model systems that may not always accurately reproduce
the cellular environment or the local chromatin structure
found under physiological conditions.
Here, we present a procedure to test whether AEI data
are consistent with a particular polymorphism inﬂuencing
expression in cis. It should be noted that AEI is charac-
terized not only by its presence or its absence but also by
which of the alleles is overexpressed with respect to the
other and by the extent of the differential expression.
Where a polymorphism inﬂuences expression in cis, the
presence and extent of AEI in an individual will depend
on whether or not the individual is heterozygous for the
cis-acting polymorphism and on the phase between cis-
acting and transcribed polymorphisms. For example, in
cases where the cis-acting polymorphism and the tran-
scribed marker are in complete linkage disequilibriumand
where no other factors modulate allelic expression, we
would expect that AEI would always be observed in in-
dividuals heterozygous for the cis-acting polymorphism
and that the same transcribed marker allele would always
be overexpressed. Therefore, if we observe consistent over-
expression of the same marker allele across different in-
dividuals, we can infer that this allele is part of a haplotype
that contains a cis-acting sequence variant that causes
overexpression.5
However, such an approach will be insufﬁcient when
the causative and expressed polymorphisms are not in
complete disequilibrium and when AEI is inﬂuenced by
other factors—for example, by additional polymorphisms.
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Figure 1. Representation of the assumptions made by the proposed method. All individuals are heterozygous M/m for the transcribed
marker, through the experimental design. The four phase-known genotypes and the corresponding three phase-unknown genotypes are
represented on the horizontal axis. The vertical diamonds represent the distribution of log AERs for each genotype. The ﬁgure illustrates
that the variances of the values within each genotype group are assumed to be equal. Cis-acting differences will be seen only in those
individuals heterozygous at the cis-acting locus; hence, the mean log expression ratio is assumed to be the same in both homozygote
groups. The cis-acting effect is allowed as a deviation from the homozygote mean. This parameterization follows from the initial
assumptions of haplotype-speciﬁc expression and of constraining the means in the two homozygote groups to be equal.
In a study reported elsewhere, we used a Markov chain–
Monte Carlo procedure to ascertain allele frequencies of
the cis-acting polymorphism and the extent of disequilib-
rium between it and the candidate polymorphism(s).6 In
that analysis, AEI was recorded as a qualitative trait (i.e.,
if it was present or absent and, if present, which allele was
overexpressed), and we assumed that it was due to a single
biallelic cis-acting change.
Here, we present a procedure that regards AEI as a quan-
titative trait and aims to ascertain if the data are consistent
with a particular polymorphism inﬂuencing expression in
cis. There are two beneﬁts to this approach. First, it enables
the use of the allelic expression ratio (AER) directly, with-
out the loss of information incurred by classifyingAEI into
discrete classes. Second, it allows for the transcribed poly-
morphism to account for some, but not necessarily all, of
the allele-speciﬁc expression differences. The variance-
components formulation leads to a likelihood-ratio frame-
work for statistical analysis. The procedure is demon-
strated using data published elsewhere.6
We ask if a biallelic polymorphism with alleles C and c
is associated with allelic expression differences. Allelic ex-
pression is assessed at an expressed biallelic marker with
alleles M and m. We designate the phase-known genotype
of an individual as “G” and the phase-unknown genotype
as “T” (see ﬁg. 1). The latter is ascertained by genotyping
the two markers. We assume that , the amount of mRNAeH
originating from an allele carrying the haplotype H, fol-
lows a log-normal distribution, with andE[log (e )]p mH H
, where does not vary between dif-2var[log (e )]p j /2 jH
ferent alleles. The model is parameterized in this way so
that the AERs can be analyzed on a logarithmic scale.7
There are four possible haplotypes—MC, Mc, mC, and
mc—and we designate the set of all possible genotypes
that these haplotypes can form as “ .” The log of the ratioG
I between the expression levels of both alleles can, there-
fore, be assumed to be normally distributed, as I ∼G
, where is parameterized asN (m ,j) mG G
m  m for the genotype MC/mc0
m p m  m for Mc/mC , (1)G 0{
m for Mc/mc or MC/mC0
and the hypothesis to be tested is . Figure 1 illustratesmp 0
the conﬁguration of the model, in terms of the four phase-
known genotypes. As conﬁgured here, this model can be
seen as equivalent to a constrained analysis of variance.
The analysis is further complicated, since only three ge-
notype groups are observed. The relative frequency of the
two phase-known genotypes (i.e., MC/mc and Mc/mC)
must be estimated. The ﬁgure also illustrates that the pa-
rameter m0 allows the transcribed allele to be associated
with an effect on AER, independently of the putative cis-
acting polymorphism under investigation.
Up to a multiplicative constant, the likelihood for a set
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Table 1. Values Taken by Function P(T/G)
Phase-Known Genotype G
Phase-Unknown
Genotype T
Mm/cc Mm/Cc Mm/CC
Mc/mc 1 0 0
Mc/mC 0 1 0
MC/mc 0 1 0
MC/mC 0 0 1
of individuals heterozygous for the transcribedmarker can
be described as
( )Lp f T ,I , i i
i
where designates the density for an individual withf (T ,I )i i
the phase-unknown genotype and an expression ratioTi
and where the index runs through all individuals inI ii
the sample. depends on , , , and the genotype fre-L m m j0
quencies denoted by . There are four underlying cat-P(G)
egories of genotype, but two of these cannot be distin-
guished at the observation level because of uncertain
haplotype phase. In such situations where observations
are treated as incomplete data, it is common to use the
expectation-maximization (EM)8 iterative procedure to
ﬁnd the maximum-likelihood solution. Historically, this
type of algorithm has been commonly used in genetics,
designated as a “gene-counting” algorithm.
For an individual, can be written asf (T ,I )i i
( ) ( ) ( ) ( )f T ,I p f I FG P T FG P G ,i i i i
GG
where . Here, denotes the den-f (I FG)p f (I ;m ,j) f (I ;m ,j)i i G i G
sity of a normal distribution, with the individual expres-
sion ratio as variate, a genotype-dependent mean ,I mi G
and a variance ; and is the probability of indi-2j P(T FG)i
vidual I having phase-unknown genotype , conditionalTi
on phase-known genotype G (values presented in ta-
ble 1). The likelihood is a function of six independent
parameters.
The EM procedure consists of two steps: (1) In the “E”
step (i.e., expectation of the missing data), previous esti-
mates of the genotype frequencies ( ) and of the var-(t)P (G)
iance and expected values ( , , and ) are used to(t) (t) (t)j m m0
estimate the probabilities that each individual has a par-
ticular phase-known genotype that is conditional on his
or her observed phase-unknown genotype and expression
ratio.
t t t( ) ( ) ( )( ) ( ) ( )P GFT ,I pf G,I FT / f g,I FT ,i i i i i i
gG
where and(t) (t) (t)f (G,I FT )p f (I FG) P (GFT ) P (GFT )pi i i i i
. (2) In the “M” step (i.e.,(t) (t)P (T FG)P (G) / P (T Fg)P (g)i igG
computation of maximum-likelihood estimates, with the
assumption of complete data), with as the(t)P (GFT ,I )i i
probability that the ith individual carries the genotype G,
new estimates for the genotype frequencies, the variance,
and the expected values are obtained.
(t1) 1 t( )( ) ( )P GpN P GFT ,I , i i
i
1
2
1
2(t1)  t t( ) ( )( ) ( )j p N 1 P GFT ,I I  m ,2  i i i G( )[ ]i GG
(t1) 1 t t( ) ( ) ( )m p N I  F m P GFT ,I ,0 i G i i( )
i GG
and
(t1) t t t( ) ( ) ( )F F( ) ( )m p I  m F P GFT ,I / F P GFT ,I , i 0 G i i G i i( )
i GG i GG
where is the number of individuals in the sample andN
characterizes the phase of the cis-acting effect, withFG
respect to the expressed polymorphism:
1 for the genotype MC/mc
F p 1 for Mc/mC .G {
0 otherwise
We alternate these two steps until the relative increase of
is smaller than a threshold (1010 in our calcula-log (L)
tions). A likelihood-ratio test is then used to compare the
model that allows optimization for , , and with them m j0
model in which is ﬁxed to be zero. The algorithm ism
implemented as an S-plus/R script and is freely available
from the AEI Web page.
We illustrate the application of this statistical method,
using data recently published elsewhere,6 on matrix me-
talloproteinase 1 (MMP1 [MIM 120353]) expression in
lung tissues, as an example. We test if rs11292517 is as-
sociated with allelic expression differences in lung tissue.
This polymorphism, often designated as “1607G/GG,”
arises from the insertion/deletion of a guanine residue in
the promoter of the gene and has been shown to be able
to inﬂuence transcription in reporter assays.9 Allelic ex-
pression of MMP1 was assessed using a transcribedmarker
in the 3′ UTR of the gene (rs5854). This polymorphism
affects an XbaI restriction site. The site is present in the
T allele and is absent in the C allele. A cDNA fragment
spanning the polymorphic site was ampliﬁed by PCR and
was restricted, and the digest was analyzed by capillary
electrophoresis. Each sample was analyzed once. Experi-
mental details can be found in the original report.6
Figure 2 shows the data for lung samples from 38 in-
dividuals grouped by promoter genotype. Represented is
the ratio of the intensities of the fragment corresponding
to the C allele to those of the larger restriction product of
the band corresponding to the T allele. For ﬁgure 2, we
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Figure 2. Expression ratio between the intensities of the band
corresponding to the T allele and of the band corresponding to
the C allele, in individuals heterozygous for rs5854. Represented
are the results for 24 gDNA samples and for 38 cDNA samples. The
latter are grouped according to the genotype at the promoter
polymorphism (rs1129251). The right Y-axis shows the range of
the observations before normalization by the gDNA mean. As can
be seen from the diagram, the normalization procedure effectively
shifts the axis by the log of the geometric mean of the gDNA
values.
Table 2. Analysis of MMP1 AER Data
Model Unrestricted m p 00 mp 0
mˆ0 .19 … .24
mˆ 1.13 1.00 …
jˆ .86 .87 1.12
ln (L) 117.5 118.1 122.6
Pa … .30 1.5#103
a With respect to the unrestricted model.
have recoded the allele with a single G as “1” and the
allele with the insertion (GG) as “2.”
Usually, ascertaining AER requires a reference where
both alleles are present in equimolar amounts for nor-
malization. Genomic DNA (gDNA) is often used for this
purpose.10 This reference should control for differences in
the ability of the detection system to quantify both alleles.
For example, if an intercalating dye is used to quantify
the amount of DNA present in a restriction fragment, the
intensity of the ﬂuorescence will depend on the size and,
perhaps, on the composition of that fragment. This situ-
ation is illustrated in ﬁgure 2. It shows the ratios for a set
of 24 gDNA samples that were used as equimolar controls.
The ratios are !1—that is, they show a bias towards the
uncut allele (the C allele). In this example, the range of
the uncorrected ratios for the gDNA was 0.35–0.69, and
the mean was 0.55. Such inﬂuences must be corrected
when comparing band intensities in an AER analysis.
Here, normalization was performed by dividing the ratio
of each of the cDNA samples by the geometric mean of
the ratios from the gDNA samples.6
The limitations of the EM algorithm, with respect to
converging to local maxima, are well established.8 As for
any algorithm of this kind, a range of different starting
values should be used. For this particular application, we
found that the EM procedure was not sensitive to starting
values for , j, or for the genotype frequencies. However,m0
two equivalent solutions corresponding to the same max-
imum likelihood were found, with respect to the sign of
the parameter m. This situation reﬂects the fact that, be-
cause of the experimental design that considers only in-
dividuals heterozygous at the transcribed marker, it is not
possible to identify which allele is associated with the
overexpression. The existence of two equivalent solutions
has no impact on the interpretation of the statistical sig-
niﬁcance of the association.
Table 2 shows the results of the likelihood analysis of
the normalized values. The inﬂuence of the promoter
polymorphism (in this example, rs11292517) is repre-
sented by the parameter (see eq. [1]). We detect a sig-m
niﬁcant association between the genotype for the pro-
moter polymorphism and allelic expression, since ﬁxing
at 0 results in a signiﬁcantly worse ﬁt ( ).3m Pp 5# 10
The parameter represents the inﬂuence of the genotypem0
at the transcribed polymorphism on expression ratio. The
effect of ﬁxing at 0 is not signiﬁcant ( ). Thism Pp .650
result suggests that the normalization used here was ad-
equate and, perhaps of more interest, that there is no sig-
niﬁcant association between the transcribed polymor-
phism and AER.
In our example, there was no signiﬁcant disequilibrium
between transcribed and promoter polymorphisms (P 1
, according to the data in the original report6). How-.05
ever, disequilibrium between causative and transcribed
polymorphisms seems to be quite common. In a survey
using microarrays,11 preferential overexpression of the
same transcribed allele was reported, across samples from
different individuals, in 83% of the transcripts showing
AEI. The parameterization used allows a separation of the
contribution from the transcribed polymorphism, char-
acterized by , from that of the putative cis-acting poly-m0
morphism, characterized by . This distinction could bem
particularly useful in exploring the effects of additional
polymorphisms, even when one of the alleles of the tran-
scribed marker is consistently overexpressed.
It should be noted that, although this analysis conﬁrms
that the promoter polymorphism is associated with the
variation in allele-speciﬁc expression levels of MMP1, it
does not explain all of the observed variability. This fact
can be deduced simply from the wide range of AERs for
a given promoter genotype. Other factors thatmightmod-
ulate the additional variability could include host-cell var-
iation in transcription-factor efﬁcacy for a given MMP1
genotype, the differential activity of alternative promoter
elements that may dilute allele-speciﬁc expression effects,
interindividual differences in the degree of epigenetic
modiﬁcation for a given promoter genotype, or the pres-
ence of additional functional SNPs. The procedure de-
scribed and applied in this report treats allelic expression
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as a quantitative trait and can be used to ascertain if a
candidate polymorphism contributes to the regulation of
expression in cis, even in cases where allelic expression is
inﬂuenced by other factors.
Web Resources
The URLs for data presented herein are as follows:
AEI Web page, http://www.dawn-teare.staff.shef.ac.uk/software
.html (for R code implementing the proposed method)
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim (for MMP1)
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